Silver Book Fact
After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who received traditional chemotherapy.
Aspinall, M and R Hamermesh. Realizing the Promise of Personalized Medicine. Harvard Bus Rev. 2007; 85(10): 108-17. https://hbr.org/2007/10/realizing-the-promise-of-personalized-medicine